CoChat

Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes

Open access
Bailey, RJ, Walker, CS, Ferner, AH, Loomes, KM, Prijic, G, Halim, A, Whiting, L, Phillips, ARJ, Hay, DL · 2012 · British Journal of Pharmacology
Cited by 101

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND PURPOSE Amylin (Amy) is an important glucoregulatory peptide and AMY receptors are clinical targets for diabetes and obesity. Human (h) AMY receptor subtypes are complexes of the calcitonin (CT) receptor with receptor activity‐modifying proteins (RAMPs); their rodent counterparts have not been characterized. To allow identification of the most clinically relevant receptor subtype, the elucidation of rat (r) AMY receptor pharmacology is necessary. EXPERIMENTAL APPROACH Receptors were transiently transfected into COS‐7 cells and cAMP responses measured in response to different agonists, with or without antagonists. Competition binding experiments were performed to determine rAmy affinity. KEY RESULTS rCT was the most potent agonist of rCT(a)receptors, whereas rAmy was most potent at rAMY 1(a)and rAMY 3(a)receptors. rAmy bound to these receptors with high affinity. Rat α‐calcitonin gene‐related peptide (CGRP) was equipotent to rAmy at both AMY receptors. Rat adrenomedullin (AM) and rAM2/intermedin activated all three receptors but were most effective at rAMY 3(a). AC187, AC413 and sCT 8‐32 were potent antagonists at all three receptors. rαCGRP 8‐37 displayed selectivity for rAMY receptors over rCT(a)receptors. rAMY 8‐37 was a weak antagonist but was more effective at rAMY 1(a)than rAMY 3(a). CONCLUSIONS AND IMPLICATIONS AMY receptors were generated by co‐expression of rCT(a)with rRAMP1 or 3, forming rAMY 1(a)and rAMY 3(a)receptors, respectively. CGRP was more potent at rAMY than at hAMY receptors. No antagonist tested was able to differentiate the rAMY receptor subtypes. The data emphasize the need for and provide a useful resource for developing new CT or AMY receptor ligands as pharmacological tools or potential clinical candidates. LINKED ARTICLES This article is part of a themed section on Secretin Family (Class B) G Protein‐Coupled Receptors. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.166.issue‐1

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2011.01717.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 101

Metadata

Authors
Bailey, R., Walker, C., Ferner, A., Loomes, K., Prijic, G., Halim, A., Whiting, L., Phillips, A., & Hay, D.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2012-04-10
Volume
166
Issue
1
Pages
151-167
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2106671885
Cited by
101
References
7
FWCI
2.14
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes. https://app.cochat.ai/papers/10.1111/j.1476-5381.2011.01717.x
The paper
Bailey, R., Walker, C., Ferner, A., Loomes, K., Prijic, G., Halim, A., Whiting, L., Phillips, A., & Hay, D. (2012). Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2011.01717.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.